Theoretical Insight into the Medicinal World of Organometallics: Macro versus Nano by Srivastava, Ruby
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 1
Theoretical Insight into the Medicinal World of
Organometallics: Macro versus Nano
Ruby Srivastava
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/67781
Abstract
Due to the unique physicochemical properties, organometallic complexes have been 
widely used in the medicinal world. These complexes have specific properties such as 
structural diversity, redox/catalytic activities, and possibility of ligand exchange. As the 
cancer therapies provided by these complexes are not always effective and have desired 
side effects, new treatment methods are needed for the successful therapies. Recent 
advances suggest that nanotechnology has also profound impact on the disease preven-
tion, diagnosis, and treatment. The delivery system based on nanotechnology has faster 
drug absorption, controlled dosage release, and minimal side-effects. This technology 
is used for the treatment of cancer till now, but soon, it will find applications to other 
diseases also. The use of nanotechnology in the field of drug delivery is to develop a 
system that improves the solubility and bioavailability of hydrophobic drugs. It is used 
to increase specificity, developing delivery system for slow release, and to design deliv-
ery vehicles that can improve the circulatory presence of drugs. As the photophysics 
of organometallic complexes is still not clear, this topic is included to discuss the latest 
developments in this field, which allows the photochemical reactions at the nanolevel.
Keywords: organometallic complexes, nanotechnology, photophysics, drug delivery, 
upconversion luminescence
1. Introduction
Organometallic chemistry deals with three basic aspects as environmental concern, biological 
aspect, and medicinal chemistry. Medicinal organometallic chemistry continues to be a major 
application for these compounds in biology. Medicinal organic chemistry has therapeutics, 
diagnostics, and theranostics effects. Medicinal organometallic complexes consist of platinum, 
ruthenium, iron, titanium, and gold among other metals. Fundamental studies have been carried 
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out on the organometallic complexes in which the mechanism of action exert their medicinal 
effect (e.g., induce cell death in cancer cells), the synthesis of new organometallic compounds and 
the development of combination therapies containing organometallic components. Research 
has shown significant progress in utilization of transition metal complexes as
1.1. Anticancer agents
The development of metal complexes with platinum as a central atom such as cisplatin or car-
boplatin had an enormous impact on current cancer chemotherapy. Cisplatin has become one of 
the most widely used drugs and is highly effective in treating several cancers such as ovarian and 
testicular cancers. The limitations of cisplatin have stimulated research in the field of platinum 
antitumor chemistry by including the reduction in toxicity of cisplatin (nausea, ear damage, vom-
iting, loss of sensation in hands, and kidney toxicity), acquired drug resistance observed in cer-
tain tumors and inefficiency of the drug against some of the commonest tumors (e.g., colon and 
breast). Due to its particular chemical structure, cisplatin offers little  possibility for improvement 
in tumor specificity and thereby reducing side effects. The other alternative complexes have at 
least one direct, covalent metal-carbon bond, having structural variety, diverse stereochemistry, 
provide control over major kinetic properties, kinetically stable, usually uncharged, and having 
low oxidation state of metal atom, so they can be used as ideal candidates for anticancer candi-
dates [1–4]. Some examples are: metallocenes [5–9], organometallic ruthenium half-sandwich 
complexes [10–14], organometallic osmium half-sandwich complexes [15–17], organometallic 
iridium and rhodium complexes [18–21], rhenium organometallics [22–24], ruthenium, osmium, 
iridium, and platinum organometallics as scaffolds for protein kinase inhibitors, metal NHC 
complexes [25, 26], and metal carbonyl complexes [27, 28].
1.2. Antibacterial agents
The biggest challenge in the antibacterial market is the issues related to the drug-resistant 
pathogens. The remedy is now to search for new compounds with new mode of action to 
overcome the resistant strains. This can be done by either the organic derivatization of old 
drugs or completely new organometallic drugs, for example, new tamoxifen [19–21, 29], pla-
tensimycin [22–24], etc.
1.3. Anti-infectant agents
Transition metal as silver is being used as the antimicrobial agent due to its low toxicity as 
compared to the other metals. For example: silver (1) sulfazine, which is used to treat burns 
to prevent the bacterial infections. Silver nitrate is given to the infants to prevent the devel-
opment of ophthalmia neonatorum. Chlorhexidine-silver sulfadiazine is an anti-infective 
metal complex against catheter infections. Organometallic complexes of Pt [30–32], Rh, Ir, 
Pd, and Os metal with active organic molecules have been reported to exhibit trypanocidal 
activity. Metal complexes of Pt (II) and Ru (II) with o-vanillin-(4-methyl thiosemicarbazone), 
and o-vinillin-(4-phenyl thiosemicarbazone), metal complexes of Ga (III), Al (III), and Fe are 
among the various other drugs [33–36].
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1.4. Anti-inflammatory agents
These complexes are also used as anti-inflammatory and antiarthritic agents. Several inject-
able transition metal complexes as sodium aurothiomalate, aurothioglucose, sodium auro-
thiopropanol and gold and silver nanoparticles conjugated with heparin derivative possess 
antiangiogenesis properties [37–39]. Gold has been used for the treatment of peripheral psori-
atic arthropathy. As a product of oxygen metabolism, superoxide anion can trigger oxidative 
injury to tissues. This activity is associated with riper fusion and inflammatory  diseases as 
well as neurological disorders such as Parkinson’s disease and Alzheimer’s disease. However, 
excess use of these complexes in arthritis causes pain and fever. NO is excellent ligand for 
 transition metal ions and these metal nitrosyls having therapeutic values. Sodium nitroprus-
side is used to treat cardiovascular diseases by releasing NO with limited usage due to the 
toxicity of CN−. Ruthenium poly aminocarboxylate complexes are also efficient NO scaven-
gers [40, 41].
1.5. Anti-diabetic agents
Diabetes is the most suffering disease among human beings. This is the disease in which the 
body do not produce insulin hormone, which is used for absorption of glucose in cells. The 
control of glucose level is done by vanadium complexes with organic ligands which are less 
toxic and have improved solubility and lipophilicity [42]. These complexes show involvement 
in the activation of prominent key components of insulin-signaling pathways [43]. Chromium 
supplementation also improves glycemia among patients of diabetes [44]. Similarly, higher 
zinc intake also lowers the risk of type 2 diabetes in women [45].
1.6. Neurological drugs
Neurological disorders are also treated by transition metal complexes. Lithium is used for 
Huntington’s chorea, tardive dyskinesia, spasmodic torticollis, Tourette’s syndrome, L-dopa 
induced hyperkinesia, Parkinsonism, organic brain disorders, drug induced delusional disor-
ders, migraine and cluster headache, periodic hypersomnolence, epilepsy, Meniere’s disease, 
and periodic hypokalemic paralysis. Lithinium inhibit the scavenging pathways for capturing 
inositol in the resynthesis of polyphosphoinositides in the brain. Zinc is also used as transmitter 
in neuronal signaling pathways.
1.7. Delivery probes and diagnostic tools
Organometallic complexes have unique properties as redox activity, Lewis acidity, electro-
philicity, valency, geometry magnetic spectroscopic, and radiochemical properties which 
can be used to measure cellular functions. Gold nanorods has been used for photoacoustic 
molecular imaging with simultaneous multiple targeting as they are less reactive and less 
toxic. The nanoparticles injected in the tumor cells increases their ability to absorb radiation of 
specific wavelength. The property is used in lymphotropic nanoparticle-enhanced magnetic 
resonance imaging of prostate cancer. As iron oxide has superparamagnetic properties so 
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they can act as negative contrast agent in magnetic resonance imaging (MRI) which is used to 
detect the sensitivity of inflamed tissues.
Transition metals exhibit different oxidation states and can interact with several negatively 
charged molecules. Due to their vital role in medicinal chemistry, we have included both 
the macro and the nanoorganometallic complexes and their structural and photophysical 
behavior in detail.
Metallocene compounds have two π-bonded cyclopentadienyl (Cpa) ligands on a metal 
atom. These compounds are also called “sandwich complexes” due to their symmetrical 
nature. Other metal complexes with cyclic π-perimeters are also named as metallocenes. 
Compounds with only one π-perimeter are classified as “half sandwich metallocenes.” The 
bis-cyclopentadienyl complexes are divided in two categories: (a) “classical” with parallel 
Cp rings and (b) “bent” metallocenes, which have other ligands bonded to the metal in 
addition to the Cp rings. Ferrocene was the first organometallic compound with antip-
roliferative properties, so the medicinal properties of the complex were investigated [3]. 
Ferrocene is nontoxic compound and can be injected, inhaled, or taken orally. It cannot 
cause major health problems [4, 5]. Another ferrocene-containing compound chloroquine 
(derivative) is used as antimalarial drug. Ferroquine has an activity-like chloroquine on 
the malaria parasite P. falciparum. The p-methoxybenzyl substituted titanocene show very 
good activity against renal cell cancer and pleura mesothelioma cell lines. Ruthenium com-
plexes have low toxicity and it has the same mechanism (ligand exchange kinetics) to those 
of platinum(II) antitumor drugs [10]. A class of ruthenium(II)-arene complexes that are 
weakly cytotoxic in vitro, [Ru(η6-p-arene)Cl
2
(1,3,5-triaza-7-phosphaadamantane)] termed 
as RAPTA, interact strongly with proteins, with the ability to discriminate binding to dif-
ferent proteins, but show a relatively low propensity to bind DNA, which is considered to 
be the main target of many metal-based drugs. Dyson et al. recently described the prepa-
ration of a series of RAPTA-type complexes with fluoro-substituted η6-arene ligands [46] 
(Figure 1). The active Pt-drug seems to be cis-coordinated by bidentate amine ligands or 
two amines (at least one -NH group on the amine) and two leaving groups with an inter-
mediate  binding strength (e.g., Cl−, SO
4
2−, citrate or oxalate) to platinum. Nonplatinum 
metals may have some different chemical behavior (oxidation state, redox potential, coor-
dination geometry, additional coordination sites, binding preferences to biomolecules as 
the HSAB (hard and soft (Lewis) acids and bases), rate of hydrolysis or kinetics of ligand 
exchange reactions and the ability to replace essential metals. Due to these differences, the 
nonplatinum metal-based compounds may have different mechanisms of action, biodistri-
bution, and biological activity.
Studies were carried out on complexes with iron, cobalt or gold, titanium, ruthenium, 
or gallium central atoms, which have shown the promising results in preclinical stud-
ies. Other metal complexes which have shown potential anticancer activity are the com-
plexes of Rh (I), Rh (III) [22, 23, 47], Ir (I), Ir (II), Ir (IV) [48, 20, 21], Os (II), and Os(III) 
[18, 49–52]. Ferrocifenes [53] exhibit anticancer activity against hormone dependent and 
hormone-independent breast cancers. Ferrocene derivatives as curcuminoids [54], andro-
gen derivatives [55], and antiandrogens derived from the nilutamide lead structure [56], 
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indolones [57], and ferrocenophane polyphenols [58] has also been used for antiprolifera-
tive activities.
Transition metal carbene complexes also feature a divalent organic ligand, which is 
 coordinated to the metal center. As these complexes are highly stable and easily derivatize, 
they can be the suitable candidates for drug development [8, 59].
Metal NHC complexes are also having pharmacological properties as novel antibacterial 
and antitumor drugs. Their mode of action is both coordinated metal–respective biological 
target-dependent thioredoxin reductase or other enzymes containing (seleno) cysteine resi-
dues in their active site for gold or DNA for copper NHC complexes (half-sandwich) [60, 32], 
ruthenium [27], or manganese [28, 61] bioorganometallic species and complex containing an 
acetylsalicylic acid (aspirin) derived ligand emerged as cytotoxic drugs.
An enormous work has been carried out by my mentor Prof. G. Narahari Sastry and 
group in the field of anticancer treatment. The research group has focused their attention 
to the  biochemical aspects of the clinical application of aromatase inhibitors with designing 
 strategies on toxicity profile, pharmacokinetics, relative potency of aromatase inhibitors, and 
pharmacophores models [62–73].
As the side effects of these complexes are unavoidable, the research was shifted to the nanotech-
nology which will have a profound impact on disease prevention, diagnosis, and treatment.
Few advantages of nanotechnology techniques are:
Figure 1. Schematic diagram of few organometallic complexes.
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1. Protect drug from degradation
2. Easily changeable physical properties due to nanosizes
3. Reduced dose size
4. Ease of drug targeting due to nanosize
5. Allow delivery of insoluble drugs
6. Longer circulation time
7. Maintain its therapeutic activity
8. Improve the oral bioavailability of the agents
9. Passive targeting of drugs to the macrophages (liver and spleen)
2. Nanoorganometallic complexes
Recent advances suggest that nanotechnology will give a better solution for disease preven-
tion, diagnosis, and treatment. It is an ideal targeting system, should have long circulating 
time, be present at appropriate concentrations at the target site, and should not lose its activity 
or therapeutic efficacy while in circulation. The increased vascular permeability coupled with 
an impaired lymphatic drainage in tumor allows an enhanced permeability and retention 
effect of the nanosystems in the tumor or inflamed tissue. Nanotechnology offers a solution 
for using the numerous chemical entities for treating brain disorders that are not clinically 
useful because of the presence of the blood-brain barrier.
The advantage of nanoparticles with potential MRI-related medical applications comprise of 
various materials, such as metals (gold, silver, and cobalt) or metal oxides (Fe
3
O
4
, TiO
2
 and 
SiO
2
) (Figure 2). Magnetic nanoparticles coated with dimercapto succinic acid (DMSA) were 
toxic to neurons in a dose-dependent manner. Cobalt (Co), gold (Au@Fe), and platinum (Pt@
Fe) are the other types of nanomaterials that show potential application in antimicrobial and 
anticancer treatment. Several studies on nanoparticles shown them to be cytotoxic [72], geno-
toxic [73], and potentially carcinogenic [74] and are used to induce apoptosis and inhibit cell 
proliferation [75].
These nanomaterials contain the sphere and core-shell structures, two-dimensional (2D) 
grapheme nanosheets have great potential for high drug loading efficiency and conjugation 
of proteins, drugs, and fluorescent probes.
The molecular imaging applies to various techniques such as positron emission tomography 
(PET), computed tomography (CT), or ultrasound and magnetic resonance imaging (MRI) 
which gives the best spatial resolution and is either noninvasive or minimally invasive. As 
MRI is not applied in full potential due to low specificity, so it can be alternatively taken to 
use as cell markers. The unique paramagnetic and superparamagnetic properties of nanopar-
ticles (NP) can be utilized for the detection with MRI in small quantities. Nanoparticles with 
potential MRI-related medical applications comprise various materials, such as metals (gold, 
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silver, and cobalt) or metal oxides (Fe
3
O
4
, TiO
2
, and SiO
2
). While diagnostic is a common 
medical application of nanoparticles, they can also be used for therapy [76–80] (Figure 3).
Nanoparticles can be categorized in two parts:
Figure 2. Schematic representation of the targeted contrast agent used for MRI approaching of the cancer cell and 
specific proteins.
Figure 3. Representation of toxicological mechanisms of NM to eukaryotic cells.
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2.1. Inorganic nanoparticles
Silver (Ag), iron oxide (Fe
3
O
4
), titanium oxide (TiO
2
), copper oxide (CuO), and zinc oxide 
(ZnO) are used for highly potent antibacterial effect. The property is exhibited through 
reactive oxygen species (ROS) generation or by physical structure and metal-ion release. 
Though the mechanism is not clear, nonetheless high surface energy may compromise their 
efficacy. Another important aspect is that how to define and determine the silver minimal 
inhibitory concentration (MIC) and breaking point, the ease of emergence of resistant strains 
[81–83]. Silver really kills biofilm or planktonic cells and finally the side effects of silver and 
its complexes [84–87] remains the same. Yet till now it is the most promising antibacterial 
nanometal. Titanium oxide (TiO
2
) has shown its efficiency against various viral species and 
parasites [88–90]. Copper oxide (CuO) is less expensive and used for efficacy enhancement 
[91–93]. Iron oxide (Fe
3
O
4
) [94], zinc oxide (ZnO) and Magnesium oxide (MgO) [95–97] 
nanoparticles show antibacterial activities. Gold nanoparticles and nanorods have been used 
as bactericidal in photothermally functionalized form [98]. Pt nanoparticles diffuse through 
membranes and induce DNA damage, accumulation of cells at the S-phase of the cell cycle, 
and apoptosis [99]. The properties of Al
2
O
3
 are unclear about the antibacterial treatment [100], 
while SiO
2
, Au, Fe
2
O
3
, and TiO
2 
are biocompatible.
Even cytotoxic NM can be converted into biocompatible materials through slight variation 
in their surface structure. Therefore, we can say that nanomaterials possess a broad level 
of biological properties that are highly dependent upon their size, structure, quantity, and 
receptor cell type. Though, the nanomaterials that penetrate the body through the skin by 
respiration or by inhalation directly affect the major body organs (lungs, heart, and brain).
2.2. Organic nanoparticles
Quaternary ammonium compounds, imidazole derivatives, alkyl pyridiniums, copolymers of 
N-vinylimidazole and phenacyl methacrylate, benzoic acid, phenol, and p-Hydroxy benzoate 
esters, quaternary phosphonium or sulfonium groups, triclosan, 5-chloro-8-hydroxy-quinoline, 
chitosan, or quaternary phosphonium are the polymeric nanoparticles that are used to kill 
microorganisms either by releasing antibiotics, antimicrobial peptides, and antimicrobial 
agents or by contact-killing cationic surfaces. Organic antibacterial materials are less stable 
than inorganic materials at high temperatures [101, 102]. Still some phenomena  such as 
 several NM killing pathways, effects of NM’s treatment combinations and bacterial intrinsic 
pathways of programmed cell death in NM’s dependent killing are yet to be understood.
As we all know, hepatocellular carcinoma (HCC) is the leading cause of cancer-associated 
death and the conventional treatment is still not satisfactory due to chemoresistance and recur-
rence. In a recent study, Pt nanocluster assembly (Pt-NA) composed of assembled Pt nanoclus-
ters was synthesized incorporating a pH-sensitive polymer and HCC-targeting  peptide [103] .
The advantage of Pt nanocluster medicine is that Pt-NA is active in peripheral blood and 
readily targets tumor cells including CLSC because of (i) the surface-targeting peptide; (ii) 
protonation of pH-sensitive polymers in an acidic intracellular environment triggers Pt-NA 
disassembly into extremely small Pt nanoclusters; and (iii) the resulting extremely small Pt 
Recent Progress in Organometallic Chemistry10
nanoclusters with large specific surface accelerate the release of toxic Pt ions inside the cells 
for an effective cancer treatment (Figure 4).
Numerous efforts have been devoted to synthesize nanostructured materials with specific 
morphology as their size and shape play an important role in determining their functions. It 
was seen that the cationic nanoparticles with metals (gold, silver, and cobalt) or metal oxides 
(Fe
3
O
4
, TiO
2
, and SiO
2
) were moderately toxic than their anionic nanoparticles. The studies 
reflect that DMSA coated nanoparticles are nontoxic to HeLa cells or RAW macrophages. 
The incorporation of chlorotoxin onto functionalized Fe
3
O
4 
nanoparticles resulted in a sig-
nificant increase in the total uptake within the brain tumors of mice. Substituted magnetic 
spinel  ferrites of the general formula MFe
2
O
4 
(where M = Zn2+, Mn2+, Co2+, Ni2+, and Mg2+) offer 
the opportunity to fine-tune the magnetic properties of the inorganic nanoparticle core as a 
function of the kind of divalent ion.
Figure 4. Schematic representation of HCC targeted Pt nanocluster assembly (Pt-NA). Adapted with permission from 
American Chemical Society [103].
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3. Photophysics of the bioactive molecules
In the recent years, new experimental and theoretical developments have occurred in the 
field of photoactivatable metal complexes which play active role in the field of medicine and 
biotechnology. Some metal-DNA complexes possess favorable emission properties, while 
some complexes also provide site-directed therapy. These properties help in oncology, where 
metal-based precursors generate excited state drugs with different mechanisms.
In this section, the computational techniques (time-dependent density functional theory) and 
ultrafast-pulsed radiation techniques will be discussed.
The delivery of light depends on the efficiency of light source. It should be efficient to 
activate the complex. The irradiation should occur in the strong MLCT transitions. However, 
in medicinal world the UV radiations are harmful but red region is preferred as it deeply 
penetrates the tissues. Two and three photon absorption can be achieved as the desirable 
condition is to activate complexes that absorb at shorter wavelength using laser beam that 
penetrates tissues deeply.
The use of organometallics has become a topic of interest for design of tractable therapeutic 
agents and theranostics [104]. The most promising organometallic complexes (and motifs) used 
in cancer therapy is RAPTA-C: [Ru(η6-p-cymene)Cl
2
(pta)] (pta = 1,3,5-triaza-phosphatricyclo 
[3.3.1.1]-decane; Chart 1), along with its osmium analogue and their corresponding function-
alized derivatives [105]. These complexes exhibit antimetastatic properties in vivo. The quite 
strongly bonded phosphine and arene ligands, the chloride ligands rapidly interchange with 
water molecules. Arene-ruthenium derivatives can react with N- and S-donors so that they can 
bind to both nucleotides and proteins [106].
Porphyrins and their metalloderivatives are used for photodynamic therapy [107] and optical 
imaging and as theranostic agents [108]. Gold (III), Palladium (II), Palladium (III) inside the 
 porphyrin rings and their derivatives can act as anticancer agents [109]. It is based on the concept 
of “optical bi-theranostic” (two modalities for therapy and one for optical imaging). Further as 
the intramolecular interactions between the two moieties alter their activities so this should be 
considered for designing and testing. Ruthenium and Iridium possess favorable photophysi-
cal properties which allow functional imaging of cells and tissues (e.g., DNA interactions) and 
provide site-directed therapy. The electronic transitions can be metal-centered (MC), ligand- 
Chart 1. Structure of [Ru(η6-p-cymene) Cl
2
(pta)] (left) and [(η5-Cp)Ti((η5-C
5
H
4
-(CH
2
)
4
-PPh
2
-[Ru(η6-p-cymene)Cl
2
(pta)] 
(right).
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centered (LC) or involve both the metal and the ligands: metal-to-ligand charge transfer (MLCT) 
(for readily oxidized metal ions and ligands with low-lying acceptor orbitals), or ligand-to-metal 
charge transfer (LMCT) (for readily reduced metal ions with strong donor ligands) (Figure 5).
A lot of research is carried out in the delivery of small molecules, which can act as sec-
ond messengers and transmit signals into cells, for example, NO, carbon monoxide (CO), 
and hydrogen sulfide (H
2
S). Photoactive Pt (IV) diazido complexes also offer potential dual 
mode activity; excited singlet and triplet states can release reactive or biologically active 
ligands and form Pt (II) species which can bind to DNA. The introduction of extended con-
jugation into the amine ligands of square–planar Pt (II) complexes has allowed two-photon 
activation of ligand exchange using red and near-infrared (NIR) light. The wavelength for 
two-photon activation of cis-[PtCl
2
(MOPEP)
2
], where MOPEP is the π-conjugated ligand 
4-[2-(4 methoxyphenyl)ethynyl]pyridine, is shorter than twice the single-photon absorption 
wavelength [110].
Another important optical phenomenon is “upconversion luminescence,” which is discussed 
here.
3.1. Upconversion luminescence
It is a nonlinear optical phenomenon, which absorb two or more photons and emit one photon. 
Compared with traditional luminescent materials, upconversion nanostructures have many 
advantages, such as weak background interference, long lifetime, low excitation energy, and 
strong tissue penetration, which are used in bioimaging and sensing. Similarly producing 
shorter wavelength light from longer wavelength irradiation involves the use of upconverting 
nanoparticles. For example: YF3 doped with lanthanide ions (Yb3+and Tm3+). Lanthanide-doped 
upconversion nanoparticles are used to mediate nitric oxide (NO) release from Roussin’s black 
salt anion [Fe
4
S
3
(NO)
7
]− in NIR light from a simple diode laser operating at 980 nm [110]. Cr (III) 
sensitizers around a central Er (III) acceptor also favor efficient nonlinear energy transfer and 
upconversion luminescence [111].
Figure 5. Schematic representation of the orbital and excited state diagram for (d6) metal complex. Spin is represented 
by arrows (↑↓) for electronic transitions. (a) Spin up is represented for electronic transition in singlet state whereas spin 
down is represented for electronic transition in triplet state. (b) Jablonski diagram.
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3.2. Imaging and binding of photo-triggered DNA
The simple and powerful strategy for selective destruction of cancer cells is to target the 
metal complexes to the tumor cells by photoactivation. Peptides releases the aqua species, 
[(η6-p-cym)Ru(bpm)(H
2
O)]2+in the visible range which bind to DNA. The other example is the 
cyclometalated iridium (III) polypyridine indole complexes, which have the intense lumines-
cence (λ
em
= 540–616 nm, τ = 0.13–5.15 μs) [112]. Another interesting feature of these complexes 
is that they can deliver CO in the body [113], for example, MnI carbonyl complex [Mn(pqa)
(CO)3]+ (pqa =(2-pyridylmethyl)(2-quinolylmethyl)amine) [114] and manganese complexes 
[115]. The release of CO from these complexes is visibly monitored by time-resolved IR spec-
troscopy [116]. This property is also used to deliver other biologically active species also. 
[Rh(bpy)2(chrysi)]3+ targets single-base mismatches in DNA by noncovalent binding in UV/
visible region. As there is deficiency of mismatch repair in cancer cells, this technique can be 
used to detect the cancer cells [117, 118]. The other luminescent N-heterocylic carbene (NHC) 
cyclometalated platinum(II) complexes, which are localized in cytoplasmic structures, do not 
interact with nucleotides [119].
4. Conclusions
Unfortunately, like the macro organometallic complexes, the nanoparticles also carry some 
serious adverse effects. Though the adverse effects of nanoparticles depend on individual 
factors such as genetics, existing disease conditions, exposure, nanoparticle chemistry, 
size, shape, agglomeration state, and electromagnetic properties, the key to understanding 
the  toxicity of nanoparticles is their size. Thus, it is very essential to understand the basic 
nature, structure, and the photophysics behind these particles. Nanoparticles are smaller 
than  mammalian cells and cellular organelles, which allows them to penetrate these bio-
logical structures and disrupt their normal function. Nanoparticles are effective in glycoma 
treatment. This brain cancer is particularly difficult to treat as neurosurgery is ineffective, 
while chemotherapy suffers from the inability of therapeutics to cross the blood. Although 
the lack of self-error-correcting mechanism result in defect sites in these nanostructures, 
the high efficiency and relative simplicity of the novel approach demonstrates the potential 
power of using irreversible covalent bonds to generate adverse range of shape-persistent 
and robust nanostructures that is likely to enrich the repertoire of self-assembled nanoma-
terials and multidrug delivery. Finally, toxicity of nanoparticles could also be potentially 
utilized to destroy the cancer cells. Bioorganometallic compounds offer hope in the fight 
against the deadly diseases such as Malaria, HIV/AIDS, and EVD that have continued to 
devastate humans. There are expected challenges in this area of collaborative research 
as organometallic compounds are ideally synthesized under inert atmosphere in the 
absence of oxygen and water. These challenges are not too difficult to surmount, we 
therefore implore researchers to orient more into this relatively new multidisciplinary 
research area in the search for novel and potent anticancer and other drug candidates 
with reduced side effects, which can be a great service to the mankind.
Recent Progress in Organometallic Chemistry14
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